ImmunityBio Inc. Common Stock vs Viasat — how do they compare? ImmunityBio Inc. Common Stock trades at $10.02 (market cap $10.33B), while Viasat trades at $69.07 (market cap $9.76B). The key difference: ImmunityBio Inc. Common Stock and Viasat are close in size by market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Viasat for 10 Days on average.
| IBRX | VSAT | |
|---|---|---|
Market Cap | $10.33B | $9.76B |
Volume | 11,745,198 | 1,739,997 |
Sector | Health | Technology |
52-Week High | $11.55 | $89.81 |
52-Week Low | $1.98 | $30.35 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $10.79B | $14.95B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →